Building oral-small-molecule programs against validated targets

ArrePath selects opportunities where target biology is validated, oral-small-molecule options are limited, and a differentiated candidate profile can be defined.

Target-specific AI/ML workflows and indication-first, multi-parameter design allow new programs to start rapidly.

Our pipeline

ArrePath pipeline: I&I Target 1, oral control of complement-mediated disease, targeting kidney and rare blood diseases, in hit-to-lead; I&I Target 2, oral control of upstream type-2 inflammation for severe asthma, in discovery; sequenced I&I opportunities, pre-prioritized targets positioned to advance as evidence emerges. Legacy antibacterial portfolio, pursuing strategic partnerships: UTI/LpxH program in late lead optimization, seeking a partner; mycobacterial programs in hit expansion and hit-to-lead.

Immunology & inflammation programs

First oral small molecules against validated I&I targets

Discovery

I&I Target 1: Oral control of alternative complement

Complement-mediated renal disease.

Discovery

I&I Target 2: Oral control of upstream type-2 inflammation

Severe asthma.

Sequenced I&I opportunities

Pre-prioritized targets positioned to advance as evidence emerges.

Antibacterial portfolio

Available for strategic partnership

UTI / LpxH program. An oral LpxH inhibitor for drug-resistant Enterobacterales, including CRE, acting through a clinically novel mechanism. The program is in late lead optimization, has received non-dilutive funding from CARB-X and PACE, and ArrePath is seeking a partner to advance it.

Mycobacterial programs. Target-specific programs for M. abscessus, broad-spectrum NTM, and tuberculosis, at hit expansion and hit-to-lead. Partnering opportunities are available.

Connect With Us

Interested in learning more about our strategy, or in discussing a
partnership? Contact us to get the conversation started.